The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701).
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly; Sanofi
 
Pamela J. Atherton
No Relationships to Disclose
 
Katie Murray
Consulting or Advisory Role - Urogen Pharma
Speakers' Bureau - Urogen Pharma
 
Young Kwok
No Relationships to Disclose
 
Preston D. Steen
No Relationships to Disclose
 
Shiva Baghaie
No Relationships to Disclose
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; EMD Serono; Intellisphere; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Advanced Accelerator Applications; Athenex; Bayer; Curium Pharma; Endocyte; Exelixis; Johnson & Johnson; Lantheus Medical Imaging; NCCN; Novartis; ORIC Pharmaceuticals; Progenics
Research Funding - Bayer (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Janssen (Inst); Progenics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Endocyte; Fujifilm